CA
NZ
UK
AU
IND
US
Key Highlights• Strong headline growth deserves deeper analysis.• Capital allocation remains the key investment variable.• Balance-sheet strength matters more in uncertain markets.• Revenue quality is as important as revenue growth.• Long-term investors should focus on cash generation.Financial markets often reward growth stories, but durable …
Key Highlights• Strong headline growth deserves deeper analysis.• Capital allocation remains the key investment variable.• Balance-sheet strength matters more in uncertain markets.• Revenue quality is as important as revenue growth.• Long-term investors should focus on cash generation.Financial markets often reward growth stories, but durable …
Key Highlights• Strong headline growth deserves deeper analysis.• Capital allocation remains the key investment variable.• Balance-sheet strength matters more in uncertain markets.• Revenue quality is as important as revenue growth.• Long-term investors should focus on cash generation.Financial markets often reward growth stories, but durable …
President Donald Trump signed the Secure America Act into law on Wednesday, June 10, 2026, in a ceremony at the Oval Office flanked by House Speaker Mike Johnson, Senator Rand Paul, and other Republican lawmakers. The bill, which passed the House 214-212 on Tuesday …
Aditxt (NASDAQ: ADTX) announced a senior secured note purchase agreement involving its wholly owned subsidiary Ignite Proteomics LLC.
PMGC Holdings (NASDAQ: ELAB) recently emphasized its ITAR-registered and AS9100-certified manufacturing capabilities as interest in space infrastructure and satellite-related projects continues to grow.
Basel Medical Group (NASDAQ: BMGL) announced that it will implement a 1-for-12 reverse stock split effective June 22, 2026.
CervoMed (NASDAQ: CRVO) announced a private placement expected to generate approximately $10.5 million in upfront gross proceeds.
Rafael Holdings (NYSE: RFL) announced the successful completion of the Last Patient Last Visit milestone for the final 96-week treatment period in its global Phase 3 TransportNPC clinical trial.
Polyrizon (NASDAQ: PLRZ) announced that the European Patent Office published its patent application covering the company's Trap & Target mucoadhesive nasal-delivery technology.
Please wait processing your request...